Endocrinology News and Research

Latest Endocrinology News and Research

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and six months ended June 30, 2010, and presented an update on recent clinical and corporate progress.

13 Aug 2010

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results for the second quarter ended June 30, 2010.

12 Aug 2010

Halozyme Therapeutics granted U.S. patent for recombinant human hyaluronidase enzyme platform

Halozyme Therapeutics, Inc. today announced the issuance of U.S. Patent No. 7,767,429 claiming its proprietary recombinant human hyaluronidase enzyme platform (rHuPH20). Claims to the human PH20 glycoprotein, PEGylated variants, the glycoprotein produced by recombinant methods, and pharmaceutical compositions with other agents, including antibodies, insulins, cytokines, anti-infectives and additional therapeutic classes were awarded in the '429 patent. Additional claims are in prosecution.

12 Aug 2010

Study offers clues to potential treatments for preserving, restoring insulin-producing cells

In type 1 diabetes, the body relentlessly attacks and destroys its own insulin-producing pancreatic beta cells. But a study by Joslin Diabetes Center scientists now has firmly established that some of these cells endure for many decades in a small group of people with the disease—offering clues to potential treatments for preserving and even restoring the crucial cell population.

12 Aug 2010

Researchers suggest Hsp70 can reverse Diabetic peripheral neuropathy

Researchers have been able to use a common chaperone protein, Hsp70, to reverse the loss of function in the nerves of mice with diabetes.Writing in ASN NEURO, Michael J. Urban and colleagues at the University of Kansas suggest that Hsp70 could be used in the future to cure the loss of feeling in the limbs that afflicts many diabetics.

12 Aug 2010

Pathway's drug development milestone triggers $4.5M tranche of Series A private equity placement

Pathway Therapeutics, a drug discovery and development company founded in New Zealand, announced that it has met an important drug development milestone triggering a US$4.5 million fourth tranche of its Series A private equity placement. The financing was led by GBS Venture Partners, Australia and CM Capital Investments, Australia with co-investors the Breast Cancer Research Trust, the Trans-Tasman Commercialisation Fund, and the New Zealand Venture Investment Firm.

12 Aug 2010

Reduced quality or quantity of sleep leads to school performance difficulties, behavior problems

Getting a good night's sleep often comes down to technique. Avoiding late-night technology use and keeping a regular sleep schedule are two important techniques to heed as kids head back to school.Recent studies found that adolescents used multiple forms of technology late into the night, including gaming systems, cell phones, and computers. As a result, they demonstrated difficulty staying awake and alert throughout the day.

12 Aug 2010

TriZetto announces general availability of health benefits administration and incentive management software

The TriZetto Group, Inc. today announced the general availability of its Value-Based Benefits Solution, health benefits administration and incentive management software that enables healthcare payers to customize benefits and provide incentives for individual members based on their health status, chronic conditions, and health and wellness activity.

12 Aug 2010

Intellect Neurosciences receives patent for insulin sensitizer drugs

Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced today that its Chairman & CEO, Dr. Daniel Chain, was granted a patent by the European Patent and Trademark Office related to the use of insulin sensitizers for the prevention and treatment of memory loss and dementia. Insulin sensitizer drugs include Rosiglitazone and Pioglitazone, which have been approved for the treatment of type II diabetes mellitus.

12 Aug 2010

Researchers develop first diabetes risk assessment for multi-ethnic population

A team from the University of Leicester, led by Professor Melanie Davies from the Department of Cardiovascular Sciences and Professor Kamlesh Khunti from the Department of Health Sciences, has developed an easy way for people to assess their risk of having diabetes. Working in partnership with Diabetes UK, the largest diabetes charity in the country, and University Hospitals of Leicester NHS Trust, they have produced the first diabetes risk assessment that can be used in a multi-ethnic population.

12 Aug 2010

Dicerna announces closing of $25 million Series B round of financing

Dicerna Pharmaceuticals, Inc., a second generation RNA interference company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and Dicer Substrate siRNA molecules, today announced that it has closed a $25 million Series B round of financing. New investor Domain Associates led the round, with all existing investors participating - Oxford Bioscience Partners, Skyline Ventures and Abingworth.

11 Aug 2010

Third round of tax-free $250 rebate checks mailed to eligible Medicare beneficiaries

Today, U.S. Department of Health and Human Services Secretary Kathleen Sebelius announced that the third round of one-time, tax-free $250 rebate checks have been mailed to eligible Medicare beneficiaries whose drug costs are so high they have reached the Medicare Part D prescription drug coverage gap known as the "donut hole."

11 Aug 2010

Repros receives US patent for Androxal

Repros Therapeutics Inc. today announced the US Patent and Trademark office has issued U.S. Patent No. 7,759,360 for Androxal, the Company's lead program for the treatment of low testosterone in men. This patent specifically claims methods and materials for the treatment of testosterone deficiency in men with secondary hypogonadism. Repros has over 35 issued or pending US and European patents involving Androxal.

11 Aug 2010

Researchers receive $1M grant to train Native American communities improve their health

UC Davis School of Medicine researchers will train Native American communities in Northern California to develop and implement culturally appropriate interventions to improve their health by decreasing obesity and type-2 diabetes, through a $1 million research grant from the National Institute of Diabetes and Kidney Diseases of the National Institutes of Health.

11 Aug 2010

NKTreg white blood cells migrate into liver, suppress immune responses: Research

After a transplant - and to assure that the new organ is not rejected - patients are put on life-long therapy to suppress their immune system, which, nevertheless, needs to be left intact enough to be able to defend the body against all kinds of disease. A tricky balance as the many rejected organs attest. But a discovery by Maria Monteiro and Luis Graça, two Portuguese scientists, could change all this, at least for the liver.

11 Aug 2010

Survey finds prevalence of diabetic retinopathy high among U.S. adults

Nearly 30 percent of U.S. adults with diabetes over the age of 40 are estimated to have diabetic retinopathy, with about 4 percent of this population having vision-threatening retinopathy, according to a study in the August 11 issue of JAMA.

11 Aug 2010

Dems continue push to sell health reform's benefits, GOP pushes back

The administration has struggled to sell senior citizens on the new health law, Politico reports. Here's why: "They know little about the early benefits the law has offered but remember last year's heated town halls, replete with death panels and rationing. And anti-health-reform rhetoric is generally proving to have considerable staying power."

11 Aug 2010

Omeros net loss for second-quarter 2010 increases to $7.8 million

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced financial results for the three and six months ended June 30, 2010.

11 Aug 2010

Telephone monitoring can save heart failure patients: Study

Chronic heart failure needs constant care and regular monitoring. Now research says remote monitoring, either over the phone or using wireless technology, helps people with heart failure live longer and stay out of hospital.

10 Aug 2010

NeuroMetrix second-quarter total revenues decrease to $3.9 million

NeuroMetrix, Inc., a health care company transforming patient care through neurotechnology, today announced its financial results for the quarter ended June 30, 2010.

10 Aug 2010

Endocrinology News and Research

Latest Endocrinology News and Research

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Halozyme Therapeutics granted U.S. patent for recombinant human hyaluronidase enzyme platform

Study offers clues to potential treatments for preserving, restoring insulin-producing cells

Researchers suggest Hsp70 can reverse Diabetic peripheral neuropathy

Pathway's drug development milestone triggers $4.5M tranche of Series A private equity placement

Reduced quality or quantity of sleep leads to school performance difficulties, behavior problems

TriZetto announces general availability of health benefits administration and incentive management software

Intellect Neurosciences receives patent for insulin sensitizer drugs

Researchers develop first diabetes risk assessment for multi-ethnic population

Dicerna announces closing of $25 million Series B round of financing

Third round of tax-free $250 rebate checks mailed to eligible Medicare beneficiaries

Repros receives US patent for Androxal

Researchers receive $1M grant to train Native American communities improve their health

NKTreg white blood cells migrate into liver, suppress immune responses: Research

Survey finds prevalence of diabetic retinopathy high among U.S. adults

Dems continue push to sell health reform's benefits, GOP pushes back

Omeros net loss for second-quarter 2010 increases to $7.8 million

Telephone monitoring can save heart failure patients: Study

NeuroMetrix second-quarter total revenues decrease to $3.9 million

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Endocrinology News and Research

Latest Endocrinology News and Research

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Newsletters you may be interested in